As part of a pioneering project in Europe, Idoven, a company specializing in the detection of cardiovascular disease using artificial intelligence, has announced a strategic collaboration with AstraZeneca to improve the early diagnosis of cardiovascular disorders, particularly heart failure (characterized by a reduction in the heart's ability to pump blood efficiently).
One of the most widespread pathologies, and the leading cause of death worldwide, cardiovascular disease often goes unrecognized and undiagnosed due to the absence of specific symptoms in the early stages of the disease.
The project led by AstraZeneca and Idoven aims to use artificial intelligence to optimize and accelerate diagnosis and follow-up of heart failure patients over 65.
" Our artificial intelligence-based platform will be able to identify patients at high risk of heart failure within minutes, with the results reviewed and confirmed by our team of cardiologists before being shared with the attending physician for further follow-up," explains Manuel Marina, cardiologist and CEO of Idoven. Patients will then be monitored remotely, using devices that create and record an electrocardiogram from the wrist. In collaboration with Idoven, this information will be shared with healthcare professionals.
